Image Credits: Guru Focus
Bionano Genomics, Inc., fixed the pricing of $10 million of a public offering of a total of 5,000,000 shares of the company’s common stock, series Ewarrants to buy up to 5,000,000 shares of bionano’s common stock and short-term series F warrants to buy up to 5,000,000 shares of the company’s common stock (including all warrants including the ‘series warrants’) at the merged public offering price of $2.00 per share and accompanying series warrant. The series warrants will have a strike price of $2.00 per share and will be quickly exercisable on issuance. The series E warrants will expire on the fifth anniversary of the date of issuance. The short-term series F warrants will expire on the eighteenth-month anniversary of the date of issuance. The closing period of the offering is predicted on or about 17th September 2025, titled to the satisfaction of customary closing conditions. H.C. Wainwright and Co. is an exclusive placement agent in this offering period.
The gross proceeds to the company from this offering are predicted to be around $10 million before the deduction of the placement agent’s fees and remaining offering expenses payable by the company. The capable additional mass gross continues to the company from the series warrants, on confirmation of full exercise on a cash basis, will reach up to $20 million. There’s no assurance that any of the series warrants have been strike. The company plans to use the net proceeds from this offering for general corporate and working capital purposes. The securities mentioned herein are offered pursuant to a registration statement on Form S-1 (file no. 333-290187), which was announced effective by the Securities and Exchange Commission (the SEC) on 16th September 2025.
The registration of this offering is the means of building a prospectus building part of the confirmed registration statement regarding this offering. The preliminary prospectus regarding this offering has been filed with the SEC and can be globally accessible via the SEC’s website at http://www.sec.gov, and the final prospectus of the offering will be attached to the SEC. On the availability of the electronic copies of the final prospectus will be accessible on the SEC's website and also at 430 Park Avenue, 3rd floor, New York, NY 10022, a H.C. Wainwright and Co. LLC address on contact.
Holding MSC in Biotechnology, Sushma Singh is a seasoned editor at Towards Healthcare, with over three years of experience delivering insightful and accurate news in the healthcare, biotechnology, and pharmaceutical domains.
